Showing 2623 results
- https://www.novartis.com/news/media-releases/novartis-renouvelle-son-engagement-lapproche-de-la-derniere-ligne-droite-dans-la-lutte-visant-eradiquer-la-lepreCe nouvel engagement sur cinq ans comprend un don de médicaments d'une valeur estimée à plus d'USD 40 millions qui devrait permettre de traiter environ 1,3 million de patients Le nouveau…
- https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-tafinlar-and-mekinist-first-combination-approved-patients-aggressive-form-melanomaApproval based on two Phase III studies demonstrating statistically significant overall survival benefit with combination therapy vs BRAF inhibitor monotherapy Targeted combination offers…
- https://www.novartis.com/news/media-releases/novartis-continues-commitment-go-last-mile-effort-eliminate-leprosyNew five-year commitment includes donation of treatments worth more than USD 40 million and is expected to reach an estimated 1.3 million patients Novartis Foundation's new leprosy contact…
- https://www.novartis.com/news/media-releases/das-novartis-international-biocamp-zeigt-wie-zusammenarbeit-und-vielfalt-innovationen-fordern-und-inspiriert-kunftige-wissenschaftliche-fuhrungskrafteDas International Biotechnology Leadership Camp (BioCamp) fördert das Interesse von Studierenden für wissenschaftlichen Fortschritt und unternehmerische Chancen Anlässlich des interaktiven Programms…
- https://www.novartis.com/news/media-releases/le-novartis-international-biocamp-souligne-le-role-de-la-collaboration-et-de-la-diversite-pour-stimuler-linnovation-et-inspirer-les-futurs-leaders-scientifiquesL'International Biotechnology Leadership Camp (BioCamp) mobilise des étudiants autour d'avancées scientifiques et d'opportunités entrepreneuriales. Ce programme interactif a réuni au siège de…
- https://www.novartis.com/news/media-releases/novartis-international-biocamp-highlights-how-collaboration-and-diversity-drive-innovation-and-inspires-future-science-leadersThe International Biotechnology Leadership Camp (BioCamp) engages students around scientific advances and entrepreneurial opportunities The interactive program brought 70 university students…
- https://www.novartis.com/news/media-releases/fda-expands-use-novartis-drug-promacta-include-treatment-children-ages-1-and-older-chronic-immune-thrombocytopeniaNew oral suspension formulation, designed for younger children with rare blood disorder, is now approved For about one in four children with ITP, the condition persists for more than 12…
- https://www.novartis.com/news/media-releases/novartis-completes-acquisition-chinook-therapeuticsAcquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfrontDeal brings two phase 3 assets in development for IgAN; atrasentan, an oral endothelin…
- https://www.novartis.com/news/media-releases/novartis-acquires-all-remaining-rights-gsks-ofatumumab-develop-treatments-ms-and-other-autoimmune-indicationsNovartis strengthens multiple sclerosis focus with the addition of Ofatumumab to leading MS portfolio which includes Gilenya and investigational treatments BAF312 and CJM112 Ofatumumab is a…
- https://www.novartis.com/news/fda-approves-novartis-millburn-facility-us-commercial-production-pluvicto
Pagination
- ‹ Previous page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- …
- 263
- › Next page